A 2026 UK Biobank MRI preprint involving 71,214 adults found that chronic pain plus current depression had a structural brain profile that was more than chronic pain plus depression pasted together. The 1,377-person comorbid group showed widespread lower cortical volume, lower bilateral thalamic and hippocampal volume, lower left accumbens volume, and broad white-matter microstructure differences …
Antibiotics have long been the cornerstone of modern medicine, but their effectiveness is increasingly threatened by the rise of antibiotic resistance. While the overuse of antibiotics is a well-acknowledged culprit, recent research reveals a surprising and relatively unexplored contributor: antidepressants. Highlights: Antidepressants and Resistance: Antidepressants, particularly those used in large quantities like SSRIs and SNRIs, …
It appears as though the pharmaceutical juggernaut Eli Lilly is facing major legal backlash for failure to disclose discontinuation effects associated with their medication Cymbalta (Duloxetine). Cymbalta is an SNRI antidepressant that was approved in August 2004 for the treatment of major depression. A woman named Claudia Herrera has been making news headlines because she …
Cymbalta (Duloxetine) is a drug that us utilized primarily to treat major depression. It was approved in 2004 by the FDA as an SNRI antidepressant, and would later receive approval for the treatment of neuropathy, fibromyalgia, and some cases of chronic pain. The fact that Cymbalta can be prescribed to treat a diverse number of conditions …
Cymbalta (Duloxetine) was officially approved by the FDA in 2004 as a new treatment for major depression. It is classified as an SNRI antidepressant which means it inhibits the reuptake of serotonin as well as norepinephrine. This medication was also devised to target more of the physical symptoms associated with depression and was approved by …